Balyasny Asset Management
EIDX

Balyasny Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Balyasny Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-297,182
Closed -$39.1M – 2251
2020
Q4 		$39.1M Buy
+297,182
New +$26.3M 0.22% 111
2018
Q4 		– Sell
-32,095
Closed -$320K – 1909
2018
Q3 		$320K Sell
32,095
-48,505
-60% -$797K ﹤0.01% 1489
2018
Q2 		$1.64M Buy
+80,600
New +$1.69M 0.01% 997

Balyasny Asset Management's EIDX Position: Q1 2021 in Review

Balyasny Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 297,182 shares — an estimated $39.1M sold.

Balyasny Asset Management first reported a position in EIDX in Q2 2018 and held it in 3 quarters. The position peaked at $39.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Balyasny Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 297,182 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $39.1M.
  • Balyasny Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Balyasny Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $39.1M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.